Key result
Factor V Leiden testing followed by 3-year anticoagulation lowers costs and adds ~0.15 QALYs vs. no testing.
Why the study?
The cost-effectiveness of testing for factor V Leiden mutation in survivors of venous thromboembolism has not been assessed.
Does testing for factor V Leiden improve cost-effectiveness in 35-year-old women with a first episode of VTE?
Does testing for factor V Leiden improve cost-effectiveness in 35-year-old women with a first episode of VTE?
No takes yet. Share an insight, caveat, or question.
Testing for factor V Leiden after VTE may not be cost-effective for most patients; leaves open selective lifelong anticoagulation only in idiopathic cases with low bleeding risk.
Eckman et al. (2002) studied Venous thromboembolism. Testing for factor V Leiden vs. No testing (oral anticoagulant therapy for 6 months) was evaluated on Cost-effectiveness (costs and quality-adjusted life years). Testing for factor V Leiden followed by 3 years of anticoagulation cost $9,676 and increased quality-adjusted life expectancy by 0.15 years compared to $10,392 for no testing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: